Sumatriptan Auto Injector Approval - Sun Keeps Up the Pace of Low Competition Launches
We reiterate our Outperform rating on Sun Pharma after it received final ANDA approval for Sumatriptan Succinate autoinjector 6 mg (base) / 0.5 ml equivalent to GSK’s Imitrex Statdose system. Sun’s product is the only AB rated generic product in the market that will compete with 2 non-AB rated generics Sumavel (from Astellas) and Alsuma (from King Pharma, now Pfizer). Sun Pharma’s addressable innovator’s brand market comprises of Imitrex injection that currently generates $190m of sales. Being the only generic equivalent in the market, Sun Pharma’s competitive positioning is the strongest.
COMPANIES MENTIONED
SUN PHARMA, SUNP
SUN PHARMA, SUNP
